New discoveries are increasing the number of biomarker/drug associations at an unprecedented rate. It is more important than ever for cancer patients to have comprehensive molecular testing on their tumors.
Whole Exome Sequencing (SNVs, Indels, Copy Number Alterations, Karyotyping* & Viruses*)
Whole Transcriptome Sequencing (Fusions, Variant Transcripts & Gene Expression*)
Immunohistochemistry (Tumor-Expressed Antigens)
The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted.
MI Tumor Seek HybridTM (NGS-based WES and WTS) plus Immunohistochemistry and Other Tests by Tumor Type. Caris FOLFIRSTaiTM reported for mCRC cases.
MI Tumor Seek HybridTM, including NGS-based whole exome sequencing and whole transcriptome sequencing. Caris FOLFIRSTai™ reported for mCRC cases.
Whole Exome Sequencing | |
---|---|
Alterations | SNVs, Indels, CNAs, Karyotyping*, Viruses* |
Genomic Signatures/Other | gLOH, MSI, TMB, HLA Genotyping*, Homologous Recombination Deficiency (HRD)* |
Whole Transcriptome Sequencing | |
---|---|
Alterations | Fusions, Variant Transcripts, Gene Expression* |
Caris GPSai™* |
---|
Cancer type similarity assessment that is intended to help identify the tumor of origin by comparing the molecular characteristics of the patient's tumor against other tumors in the Caris database. |
Caris FOLFIRSTai™* |
---|
Chemotherapy response predictor that is intended to gauge a mCRC patient's likelihood of benefit from first-line FOLFOX+BV followed by FOLFIRI+BV, versus FOLFIRI+BV followed by FOLFOX+BV treatment. |
MMR = Mismatch Repair proteins: MLH1, MSH2, MSH6, PMS2 †ALK IHC only performed for NSCLC adenocarcinoma.
#FOLR1 IHC and HRD Status only performed for epithelial ovarian cancer.
^Ki-67 IHC only for early stage breast cancer.
* Not available in all locations.
Tumor Type | Immunohistochemistry (IHC) | Other |
---|---|---|
Bladder | MMR, PD-L1 (SP142, 22c3) | |
Breast | AR, ER, Her2/Neu, Ki-67^, PD-L1 (22c3), PR, PTEN | |
Cancer of Unknown Primary – Female | AR, ER, Her2/Neu, MMR, PD-L1 (SP142) | |
Cancer of Unknown Primary – Male | AR, HER2/Neu, MMR, PD-L1 (SP142) | |
Cervical | ER, MMR, PD-L1 (22c3), PR | |
Cholangiocarcinoma/ Hepatobiliary | Her2/Neu, MMR, PD-L1 (SP142) | Her2 (Chromogenic in situ Hybridization) |
Colorectal and Small Intestinal | Her2/Neu, MMR, PD-L1 (SP142), PTEN | |
Endometrial | ER, MMR, PD-L1 (SP142), PR, PTEN | |
Esophageal Cancer | Her2/Neu, MMR, PD-L1 (22c3) | |
Gastric/GEJ | Her2/Neu, MMR, PD-L1 (22c3) | EBER, Her2 (Chromogenic in situ Hybridization) |
GIST | MMR, PD-L1 (SP142), PTEN | |
Glioma | PD-L1 (SP142) | MGMT Methylation (Pyrosequencing) |
Head & Neck | MMR, p16, PD-L1 (22c3) | EBER, HPV (Chromogenic in situ Hybridization), HPV reflex to confirm p16 result |
Kidney | MMR, PD-L1 (SP142) | |
Lymphoma/Leukemia | ||
Melanoma | MMR, PD-L1 (SP142) | |
Merkel Cell | MMR, PD-L1 (SP142) | |
Neuroendocrine | MMR, PD-L1 (SP142) | |
Non-Small Cell Lung | ALK†, PD-L1 (22c3, 28-8, SP142, SP263) | |
Ovarian | ER, FOLR1#, MMR, PD-L1 (22c3), PR | |
Pancreatic | MMR, PD-L1 (SP142) | |
Prostate | AR, MMR, PD-L1 (SP142) | |
Salivary Gland | AR, Her2/Neu, MMR, PD-L1 (SP142) | |
Sarcoma | MMR, PD-L1 (SP142) | |
Small Cell Lung | PD-L1 (22c3) | |
Thyroid | MMR, PD-L1 (SP142) | |
Uterine Serous | ER, Her2/Neu, MMR, PD-L1 (SP142), PR, PTEN | Her2 (Chromogenic in situ Hybridization) |
Vulvar Cancer (SCC) | MMR, PD-L1 (22c3) | |
Other Tumors | MMR, PD-L1 (SP142) | |
MMR = Mismatch Repair proteins: MLH1, MSH2, MSH6, PMS2 †ALK IHC only performed for NSCLC adenocarcinoma. #FOLR1 IHC and HRD Status only performed for epithelial ovarian cancer. ^Ki-67 IHC only for early stage breast cancer. * Not available in all locations. |
Place an order today for a comprehensive, personalized Caris profiling report.
Sufficient tumor content (>20% tumor nuclei) must be present to complete all analyses. If you have any questions, please contact Customer Support at (888) 979-8669.
Technical Information | IHC | CISH |
---|---|---|
Sample Requirements (see requisition for full details) |
1 unstained slide at 4μm thickness from FFPE block, with evaluable tumor present, per IHC test | 1 unstained slide at 4μm thickness from FFPE block, with at least 100 evaluable tumor cells present, per CISH test |
Sensitivity/Specificity | >95% | >95% |
Technical Information | NGS (Whole Exome – DNA) | NGS (Whole Transcriptome – RNA) |
---|---|---|
Sample Requirements | FFPE block or 10 unstained slides with a minimum of 20% malignant origin for DNA and 10% malignant origin for RNA. Needle biopsy is also acceptable (4-6 cores). | |
Tumor Enrichment (when necessary) | Microdissection to isolate and increase the number of cancer cells to improve test performance and increase the chance for successful testing from small tumor samples | |
Number of Genes | 23,000+ genes | 23,000+ genes |
Average Depth
of Coverage (DNA) Average Read Count (RNA) |
800x for clinical genes | 23 million reads |
Positive Percent Agreement (PPA) | >95% for base substitutions at ≥ 5% mutant allele frequency; >95% for indels at ≥ 5% mutant allele frequency; >90% for copy number alterations (amplifications ≥ 6 copies) |
>97% |
Negative Percent Agreement (NPA) | >99% | >99% |
Viruses* | HPV 16 & 18 (Head & Neck, Anal, Genital, CUP) | |
Genomic Signatures/Other | Genomic Loss of
Heterozygosity (gLOH) Homologous Recombination Deficiency (HRD)* Microsatellite Instability (MSI) Tumor Mutational Burden (TMB) Human Leukocyte Antigen (HLA) Genotype* |
|
* Not available in all locations. |
ABL | ABL1 | ACVR1 | AIP | AKT1 | AKT2 | AKT3 | ALK | AMER1 | APC |
AR | ARAF | ARHGAP26 | ARHGAP35 | ARID1A | ARID2 | AR-V7 | ASXL1 | ATM | ATR |
ATRX | AXIN1 | AXIN2 | AXL | B2M | BAP1 | BARD1 | BCL2 | BCL9 | BCOR |
BCR | BLM | BMPR1A | BRAF | BRCA1 | BRCA2 | BRD3 | BRD4 | BRIP1 | BTK |
CALR | CARD11 | CASP8 | CBFB | CCND1 | CCND2 | CCND3 | CD79B | CDC73 | CDH1 |
CDK12 | CDK4 | CDK6 | CDKN1B | CDKN2A | CHEK1 | CHEK2 | CIC | CREBBP | CSF1R |
CTCF | CTNNA1 | CTNNB1 | CXCR4 | CYLD | CYP17A1 | DDR2 | DICER1 | DNMT3A | EGFR |
EGFR vIII | EGLN1 | ELF3 | EP300 | EPHA2 | ERBB2 | ERBB3 | ERBB4 | ERCC2 | ERG |
ESR1 | ETV1 | ETV4 | ETV5 | ETV6 | EWSR1 | EXO1 | EZH2 | FANCA | FANCB |
FANCC | FANCD2 | FANCE | FANCF | FANCG | FANCI | FANCL | FANCM | FAS | FAT1 |
FBXW7 | FGFR1 | FGFR2 | FGFR3 | FGFR4 | FGR | FH | FLCN | FLT1 | FLT3 |
FLT4 | FOXA1 | FOXL2 | FUBP1 | FYN | GALNT12 | GATA3 | GLI2 | GNA11 | GNA13 |
GNAQ | GNAS | H3F3A | H3F3B | HDAC1 | HIST1H3B | HIST1H3C | HNF1A | HOXB13 | HRAS |
IDH1 | IDH2 | INSR | IRF4 | JAK1 | JAK2 | JAK3 | KDM5C | KDM6A | KDR |
KEAP1 | KIF1B | KIT | KLF4 | KMT2A | KMT2C | KMT2D | KRAS | LCK | LYN |
LZTR1 | MAML2 | MAP2K1 | MAP2K2 | MAP2K4 | MAP3K1 | MAPK1 | MAPK3 | MAST1 | MAST2 |
MAX | MED12 | MEF2B | MEN1 | MET | MET Exon 14 Skipping | MGA | MITF | MLH1 | MLH3 |
MPL | MRE11 | MSH2 | MSH3 | MSH6 | MSMB | MST1R | MTOR | MUSK | MUTYH |
MYB | MYC | MYCN | MYD88 | NBN | NF1 | NF2 | NFE2L2 | NFKBIA | NOTCH1 |
NOTCH2 | NPM1 | NRAS | NRG1 | NSD1 | NTHL1 | NTRK1 | NTRK2 | NTRK3 | NUMBL |
NUTM1 | PALB2 | PARP1 | PBRM1 | PDGFRA | PDGFRB | PHOX2B | PIK3CA | PIK3CB | PIK3R1 |
PIK3R2 | PIM1 | PKN1 | PMS1 | PMS2 | POLD1 | POLD2 | POLD3 | POLD4 | POLE |
POLQ | POT1 | PPARG | PPP2R1A | PPP2R2A | PRDM1 | PRKACA | PRKAR1A | PRKCA | PRKCB |
PRKDC | PTCH1 | PTEN | PTPN11 | RABL3 | RAC1 | RAD50 | RAD51B | RAD51C | RAD51D |
RAD54L | RAF1 | RASA1 | RB1 | RELA | RET | RHOA | RNF43 | ROS1 | RPA1 |
RPA2 | RPA3 | RPA4 | RSPO2 | RSPO3 | RUNX1 | SDHA | SDHAF2 | SDHB | SDHC |
SDHD | SETD2 | SF3B1 | SMAD2 | SMAD4 | SMARCA4 | SMARCB1 | SMARCE1 | SMO | SOCS1 |
SPEN | SPOP | SRC | SSBP1 | STAG2 | STAT3 | STK11 | SUFU | SUZ12 | TCF7L2 |
TERT | TET2 | TFE3 | TFEB | THADA | TMEM127 | TMPRSS2 | TNFAIP3 | TNFRSF14 | TP53 |
TRAF7 | TSC1 | TSC2 | U2AF1 | VHL | WRN | WT1 | XPO1 | XRCC1 | XRCC2 |
YES1 |
The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted.
The technology platforms used and biomarkers tested may vary based on the tumor type submitted. Technologies include: NGS (whole exome sequencing for DNA mutations, copy number alterations, insertions/deletions, genomic signatures: LOH, MSI, TMB; and whole transcriptome sequencing for RNA fusions and variant transcripts), pyro sequencing, IHC, in situ hybridization.
Whole exome sequencing for DNA mutations, copy number alterations, insertions/deletions, genomic signatures LOH, MSI, and TMB, and whole transcriptome sequencing for RNA fusions and variant transcripts. Add Immuno-Oncology IHC biomarkers (included in MI Profile):
Whole Exome Sequencing | |
---|---|
Alterations | SNVs, Indels, CNAs |
Genomic Signatures/Other | gLOH, MSI, TMB |
Whole Transcriptome Sequencing | |
---|---|
Alterations | Fusions, Variant Transcripts |
MMR = Mismatch Repair proteins: MLH1, MSH2, MSH6, PMS2 †ALK IHC only performed for NSCLC adenocarcinoma.
#FOLR1 IHC performed for epithelial ovarian cancer.
^Ki-67 IHC only for early stage breast cancer.
* Not available in all locations.
Tumor Type | Immunohistochemistry (IHC) | Other |
---|---|---|
Bladder | MMR, PD-L1 (SP142, 22c3) | |
Breast | AR, ER, Her2/Neu, Ki-67^, PD-L1 (22c3), PR, PTEN | |
Cancer of Unknown Primary – Female | AR, ER, Her2/Neu, MMR, PD-L1 (SP142) | |
Cancer of Unknown Primary – Male | AR, HER2/Neu, MMR, PD-L1 (SP142) | |
Cervical | ER, MMR, PD-L1 (22c3), PR | |
Cholangiocarcinoma/ Hepatobiliary | Her2/Neu, MMR, PD-L1 (SP142) | Her2 (Chromogenic in situ Hybridization) |
Colorectal and Small Intestinal | Her2/Neu, MMR, PD-L1 (SP142), PTEN | |
Endometrial | ER, MMR, PD-L1 (SP142), PR, PTEN | |
Esophageal Cancer | Her2/Neu, MMR, PD-L1 (22c3) | |
Gastric/GEJ | Her2/Neu, MMR, PD-L1 (22c3) | EBER, Her2 (Chromogenic in situ Hybridization) |
GIST | MMR, PD-L1 (SP142), PTEN | |
Glioma | PD-L1 (SP142) | MGMT Methylation (Pyrosequencing) |
Head & Neck | MMR, p16, PD-L1 (22c3) | EBER, HPV (Chromogenic in situ Hybridization), HPV reflex to confirm p16 result |
Kidney | MMR, PD-L1 (SP142) | |
Lymphoma/Leukemia | ||
Melanoma | MMR, PD-L1 (SP142) | |
Merkel Cell | MMR, PD-L1 (SP142) | |
Neuroendocrine | MMR, PD-L1 (SP142) | |
Non-Small Cell Lung | ALK†, PD-L1 (22c3, 28-8, SP142, SP263) | |
Ovarian | ER, FOLR1#, MMR, PD-L1 (22c3), PR | |
Pancreatic | MMR, PD-L1 (SP142) | |
Prostate | AR, MMR, PD-L1 (SP142) | |
Salivary Gland | AR, Her2/Neu, MMR, PD-L1 (SP142) | |
Sarcoma | MMR, PD-L1 (SP142) | |
Small Cell Lung | PD-L1 (22c3) | |
Thyroid | MMR, PD-L1 (SP142) | |
Uterine Serous | ER, Her2/Neu, MMR, PD-L1 (SP142), PR, PTEN | Her2 (Chromogenic in situ Hybridization) |
Vulvar Cancer (SCC) | MMR, PD-L1 (22c3) | |
Other Tumors | MMR, PD-L1 (SP142) | |
MMR = Mismatch Repair proteins: MLH1, MSH2, MSH6, PMS2 †ALK IHC only performed for NSCLC adenocarcinoma. #FOLR1 IHC performed for epithelial ovarian cancer. ^Ki-67 IHC only for early stage breast cancer. * Not available in all locations. |
Place an order today for a comprehensive, personalized Caris profiling report.
Sufficient tumor content (>20% tumor nuclei) must be present to complete all analyses. If you have any questions, please contact Customer Support at (888) 979-8669.
Technical Information | IHC | CISH |
---|---|---|
Sample Requirements (see requisition for full details) |
1 unstained slide at 4μm thickness from FFPE block, with evaluable tumor present, per IHC test | 1 unstained slide at 4μm thickness from FFPE block, with at least 100 evaluable tumor cells present, per CISH test |
Sensitivity/Specificity | >95% | >95% |
Technical Information | NGS (Whole Exome – DNA) | NGS (Whole Transcriptome – RNA) |
---|---|---|
Sample Requirements | FFPE block or 10 unstained slides with a minimum of 20% malignant origin for DNA and 10% malignant origin for RNA. Needle biopsy is also acceptable (4-6 cores). | |
Tumor Enrichment (when necessary) | Microdissection to isolate and increase the number of cancer cells to improve test performance and increase the chance for successful testing from small tumor samples | |
Number of Genes | 22,000+ genes | 22,000+ genes |
Average Depth
of Coverage (DNA) Average Read Count (RNA) |
1,000x for 719+ genes; 400-500x for all other genes | 60 million reads |
Positive Percent Agreement (PPA) | >95% for base substitutions at ≥ 5% mutant allele frequency; >95% for indels at ≥ 5% mutant allele frequency; >90% for copy number alterations (amplifications ≥ 6 copies) |
>97% |
Negative Percent Agreement (NPA) | >99% | >99% |
Genomic Signatures/Other | Genomic Loss of
Heterozygosity (gLOH) Microsatellite Instability (MSI) Tumor Mutational Burden (TMB) | |
* Not available in all locations. |
ABL | ABL1 | ACVR1 | AIP | AKT1 | AKT2 | AKT3 | ALK | AMER1 | APC |
AR | ARAF | ARHGAP26 | ARHGAP35 | ARID1A | ARID2 | AR-V7 | ASXL1 | ATM | ATR |
ATRX | AXIN1 | AXIN2 | AXL | B2M | BAP1 | BARD1 | BCL2 | BCL9 | BCOR |
BCR | BLM | BMPR1A | BRAF | BRCA1 | BRCA2 | BRD3 | BRD4 | BRIP1 | BTK |
CALR | CARD11 | CASP8 | CBFB | CCND1 | CCND2 | CCND3 | CD79B | CDC73 | CDH1 |
CDK12 | CDK4 | CDK6 | CDKN1B | CDKN2A | CHEK1 | CHEK2 | CIC | CREBBP | CSF1R |
CTCF | CTNNA1 | CTNNB1 | CXCR4 | CYLD | CYP17A1 | DDR2 | DICER1 | DNMT3A | EGFR |
EGFR vIII | EGLN1 | ELF3 | EP300 | EPHA2 | ERBB2 | ERBB3 | ERBB4 | ERCC2 | ERG |
ESR1 | ETV1 | ETV4 | ETV5 | ETV6 | EWSR1 | EXO1 | EZH2 | FANCA | FANCB |
FANCC | FANCD2 | FANCE | FANCF | FANCG | FANCI | FANCL | FANCM | FAS | FAT1 |
FBXW7 | FGFR1 | FGFR2 | FGFR3 | FGFR4 | FGR | FH | FLCN | FLT1 | FLT3 |
FLT4 | FOXA1 | FOXL2 | FUBP1 | FYN | GALNT12 | GATA3 | GLI2 | GNA11 | GNA13 |
GNAQ | GNAS | H3F3A | H3F3B | HDAC1 | HIST1H3B | HIST1H3C | HNF1A | HOXB13 | HRAS |
IDH1 | IDH2 | INSR | IRF4 | JAK1 | JAK2 | JAK3 | KDM5C | KDM6A | KDR |
KEAP1 | KIF1B | KIT | KLF4 | KMT2A | KMT2C | KMT2D | KRAS | LCK | LYN |
LZTR1 | MAML2 | MAP2K1 | MAP2K2 | MAP2K4 | MAP3K1 | MAPK1 | MAPK3 | MAST1 | MAST2 |
MAX | MED12 | MEF2B | MEN1 | MET | MET Exon 14 Skipping | MGA | MITF | MLH1 | MLH3 |
MPL | MRE11 | MSH2 | MSH3 | MSH6 | MSMB | MST1R | MTOR | MUSK | MUTYH |
MYB | MYC | MYCN | MYD88 | NBN | NF1 | NF2 | NFE2L2 | NFKBIA | NOTCH1 |
NOTCH2 | NPM1 | NRAS | NRG1 | NSD1 | NTHL1 | NTRK1 | NTRK2 | NTRK3 | NUMBL |
NUTM1 | PALB2 | PARP1 | PBRM1 | PDGFRA | PDGFRB | PHOX2B | PIK3CA | PIK3CB | PIK3R1 |
PIK3R2 | PIM1 | PKN1 | PMS1 | PMS2 | POLD1 | POLD2 | POLD3 | POLD4 | POLE |
POLQ | POT1 | PPARG | PPP2R1A | PPP2R2A | PRDM1 | PRKACA | PRKAR1A | PRKCA | PRKCB |
PRKDC | PTCH1 | PTEN | PTPN11 | RABL3 | RAC1 | RAD50 | RAD51B | RAD51C | RAD51D |
RAD54L | RAF1 | RASA1 | RB1 | RELA | RET | RHOA | RNF43 | ROS1 | RPA1 |
RPA2 | RPA3 | RPA4 | RSPO2 | RSPO3 | RUNX1 | SDHA | SDHAF2 | SDHB | SDHC |
SDHD | SETD2 | SF3B1 | SMAD2 | SMAD4 | SMARCA4 | SMARCB1 | SMARCE1 | SMO | SOCS1 |
SPEN | SPOP | SRC | SSBP1 | STAG2 | STAT3 | STK11 | SUFU | SUZ12 | TCF7L2 |
TERT | TET2 | TFE3 | TFEB | THADA | TMEM127 | TMPRSS2 | TNFAIP3 | TNFRSF14 | TP53 |
TRAF7 | TSC1 | TSC2 | U2AF1 | VHL | WRN | WT1 | XPO1 | XRCC1 | XRCC2 |
YES1 |
The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted.
Next-Generation Sequencing analysis. Whole exome sequencing and whole transcriptome sequencing are performed.
Caris GPSai™* |
---|
Cancer type similarity assessment that is intended to help identify the tumor of origin by comparing the molecular characteristics of the patient's tumor against other tumors in the Caris database. |
Caris FOLFIRSTai™* |
---|
Chemotherapy response predictor that is intended to gauge a mCRC patient's likelihood of benefit from first-line FOLFOX+BV followed by FOLFIRI+BV, versus FOLFIRI+BV followed by FOLFOX+BV treatment. |
Whole Exome Sequencing | |
---|---|
Alterations | SNVs, Indels, CNAs, Karyotyping,* Viruses* |
Genomic Signatures/Other | gLOH, MSI, TMB, HLA Genotyping* |
Whole Transcriptome Sequencing | |
---|---|
Alterations | Fusions, Variant Transcripts, Gene Expression* |
Place an order today for a comprehensive, personalized Caris profiling report.
Sufficient tumor content (>20% tumor nuclei) must be present to complete all analyses. If you have any questions, please contact Customer Support at (888) 979-8669.
Technical Information | NGS (Whole Exome – DNA) | NGS (Whole Transcriptome – RNA) |
---|---|---|
Sample Requirements | FFPE block or 10 unstained slides with a minimum of 20% malignant origin for DNA and 10% malignant origin for RNA. Needle biopsy is also acceptable (4-6 cores). | |
Tumor Enrichment (when necessary) | Microdissection to isolate and increase the number of cancer cells to improve test performance and increase the chance for successful testing from small tumor samples | |
Number of Genes | 22,000+ genes | 22,000+ genes |
Average Depth
of Coverage (DNA) Average Read Count (RNA) |
1,000x for 719+ genes; 400-500x for all other genes | 60 million reads |
Positive Percent Agreement (PPA) | >95% for base substitutions at ≥ 5% mutant allele frequency; >95% for indels at ≥ 5% mutant allele frequency; >90% for copy number alterations (amplifications ≥ 6 copies) |
>97% |
Negative Percent Agreement (NPA) | >99% | >99% |
Genomic Signatures/Other | Genomic Loss of
Heterozygosity (gLOH) Microsatellite Instability (MSI) Tumor Mutational Burden (TMB) Human Leukocyte Antigen (HLA) Genotype* | |
* Not available in all locations. |
ABL | ABL1 | ACVR1 | AIP | AKT1 | AKT2 | AKT3 | ALK | AMER1 | APC |
AR | ARAF | ARHGAP26 | ARHGAP35 | ARID1A | ARID2 | AR-V7 | ASXL1 | ATM | ATR |
ATRX | AXIN1 | AXIN2 | AXL | B2M | BAP1 | BARD1 | BCL2 | BCL9 | BCOR |
BCR | BLM | BMPR1A | BRAF | BRCA1 | BRCA2 | BRD3 | BRD4 | BRIP1 | BTK |
CALR | CARD11 | CASP8 | CBFB | CCND1 | CCND2 | CCND3 | CD79B | CDC73 | CDH1 |
CDK12 | CDK4 | CDK6 | CDKN1B | CDKN2A | CHEK1 | CHEK2 | CIC | CREBBP | CSF1R |
CTCF | CTNNA1 | CTNNB1 | CXCR4 | CYLD | CYP17A1 | DDR2 | DICER1 | DNMT3A | EGFR |
EGFR vIII | EGLN1 | ELF3 | EP300 | EPHA2 | ERBB2 | ERBB3 | ERBB4 | ERCC2 | ERG |
ESR1 | ETV1 | ETV4 | ETV5 | ETV6 | EWSR1 | EXO1 | EZH2 | FANCA | FANCB |
FANCC | FANCD2 | FANCE | FANCF | FANCG | FANCI | FANCL | FANCM | FAS | FAT1 |
FBXW7 | FGFR1 | FGFR2 | FGFR3 | FGFR4 | FGR | FH | FLCN | FLT1 | FLT3 |
FLT4 | FOXA1 | FOXL2 | FUBP1 | FYN | GALNT12 | GATA3 | GLI2 | GNA11 | GNA13 |
GNAQ | GNAS | H3F3A | H3F3B | HDAC1 | HIST1H3B | HIST1H3C | HNF1A | HOXB13 | HRAS |
IDH1 | IDH2 | INSR | IRF4 | JAK1 | JAK2 | JAK3 | KDM5C | KDM6A | KDR |
KEAP1 | KIF1B | KIT | KLF4 | KMT2A | KMT2C | KMT2D | KRAS | LCK | LYN |
LZTR1 | MAML2 | MAP2K1 | MAP2K2 | MAP2K4 | MAP3K1 | MAPK1 | MAPK3 | MAST1 | MAST2 |
MAX | MED12 | MEF2B | MEN1 | MET | MET Exon 14 Skipping | MGA | MITF | MLH1 | MLH3 |
MPL | MRE11 | MSH2 | MSH3 | MSH6 | MSMB | MST1R | MTOR | MUSK | MUTYH |
MYB | MYC | MYCN | MYD88 | NBN | NF1 | NF2 | NFE2L2 | NFKBIA | NOTCH1 |
NOTCH2 | NPM1 | NRAS | NRG1 | NSD1 | NTHL1 | NTRK1 | NTRK2 | NTRK3 | NUMBL |
NUTM1 | PALB2 | PARP1 | PBRM1 | PDGFRA | PDGFRB | PHOX2B | PIK3CA | PIK3CB | PIK3R1 |
PIK3R2 | PIM1 | PKN1 | PMS1 | PMS2 | POLD1 | POLD2 | POLD3 | POLD4 | POLE |
POLQ | POT1 | PPARG | PPP2R1A | PPP2R2A | PRDM1 | PRKACA | PRKAR1A | PRKCA | PRKCB |
PRKDC | PTCH1 | PTEN | PTPN11 | RABL3 | RAC1 | RAD50 | RAD51B | RAD51C | RAD51D |
RAD54L | RAF1 | RASA1 | RB1 | RELA | RET | RHOA | RNF43 | ROS1 | RPA1 |
RPA2 | RPA3 | RPA4 | RSPO2 | RSPO3 | RUNX1 | SDHA | SDHAF2 | SDHB | SDHC |
SDHD | SETD2 | SF3B1 | SMAD2 | SMAD4 | SMARCA4 | SMARCB1 | SMARCE1 | SMO | SOCS1 |
SPEN | SPOP | SRC | SSBP1 | STAG2 | STAT3 | STK11 | SUFU | SUZ12 | TCF7L2 |
TERT | TET2 | TFE3 | TFEB | THADA | TMEM127 | TMPRSS2 | TNFAIP3 | TNFRSF14 | TP53 |
TRAF7 | TSC1 | TSC2 | U2AF1 | VHL | WRN | WT1 | XPO1 | XRCC1 | XRCC2 |
YES1 |
The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted.
MI Tumor Seek HybridTM (NGS-based WES and WTS) plus Immunohistochemistry and Other Tests by Tumor Type. Caris FOLFIRSTaiTM reported for mCRC cases.
MI Tumor Seek HybridTM, including NGS-based whole exome sequencing and whole transcriptome sequencing. Caris FOLFIRSTai™ reported for mCRC cases.
Whole Exome Sequencing | |
---|---|
Alterations | SNVs, Indels, CNAs, Karyotyping*, Viruses* |
Genomic Signatures/Other | gLOH, MSI, TMB, HLA Genotyping*, Homologous Recombination Deficiency (HRD)* |
Whole Transcriptome Sequencing | |
---|---|
Alterations | Fusions, Variant Transcripts, Gene Expression* |
Caris GPSai™* |
---|
Cancer type similarity assessment that is intended to help identify the tumor of origin by comparing the molecular characteristics of the patient's tumor against other tumors in the Caris database. |
Caris FOLFIRSTai™* |
---|
Chemotherapy response predictor that is intended to gauge a mCRC patient's likelihood of benefit from first-line FOLFOX+BV followed by FOLFIRI+BV, versus FOLFIRI+BV followed by FOLFOX+BV treatment. |
MMR = Mismatch Repair proteins: MLH1, MSH2, MSH6, PMS2 †ALK IHC only performed for NSCLC adenocarcinoma.
#FOLR1 IHC and HRD Status only performed for epithelial ovarian cancer.
^Ki-67 IHC only for early stage breast cancer.
* Not available in all locations.
Tumor Type | Immunohistochemistry (IHC) | Other |
---|---|---|
Bladder | MMR, PD-L1 (SP142, 22c3) | |
Breast | AR, ER, Her2/Neu, Ki-67^, PD-L1 (22c3), PR, PTEN | |
Cancer of Unknown Primary – Female | AR, ER, Her2/Neu, MMR, PD-L1 (SP142) | |
Cancer of Unknown Primary – Male | AR, HER2/Neu, MMR, PD-L1 (SP142) | |
Cervical | ER, MMR, PD-L1 (22c3), PR | |
Cholangiocarcinoma/ Hepatobiliary | Her2/Neu, MMR, PD-L1 (SP142) | Her2 (Chromogenic in situ Hybridization) |
Colorectal and Small Intestinal | Her2/Neu, MMR, PD-L1 (SP142), PTEN | |
Endometrial | ER, MMR, PD-L1 (SP142), PR, PTEN | |
Esophageal Cancer | Her2/Neu, MMR, PD-L1 (22c3) | |
Gastric/GEJ | Her2/Neu, MMR, PD-L1 (22c3) | EBER, Her2 (Chromogenic in situ Hybridization) |
GIST | MMR, PD-L1 (SP142), PTEN | |
Glioma | PD-L1 (SP142) | MGMT Methylation (Pyrosequencing) |
Head & Neck | MMR, p16, PD-L1 (22c3) | EBER, HPV (Chromogenic in situ Hybridization), HPV reflex to confirm p16 result |
Kidney | MMR, PD-L1 (SP142) | |
Lymphoma/Leukemia | ||
Melanoma | MMR, PD-L1 (SP142) | |
Merkel Cell | MMR, PD-L1 (SP142) | |
Neuroendocrine | MMR, PD-L1 (SP142) | |
Non-Small Cell Lung | ALK†, PD-L1 (22c3, 28-8, SP142, SP263) | |
Ovarian | ER, FOLR1#, MMR, PD-L1 (22c3), PR | |
Pancreatic | MMR, PD-L1 (SP142) | |
Prostate | AR, MMR, PD-L1 (SP142) | |
Salivary Gland | AR, Her2/Neu, MMR, PD-L1 (SP142) | |
Sarcoma | MMR, PD-L1 (SP142) | |
Small Cell Lung | PD-L1 (22c3) | |
Thyroid | MMR, PD-L1 (SP142) | |
Uterine Serous | ER, Her2/Neu, MMR, PD-L1 (SP142), PR, PTEN | Her2 (Chromogenic in situ Hybridization) |
Vulvar Cancer (SCC) | MMR, PD-L1 (22c3) | |
Other Tumors | MMR, PD-L1 (SP142) | |
MMR = Mismatch Repair proteins: MLH1, MSH2, MSH6, PMS2 †ALK IHC only performed for NSCLC adenocarcinoma. #FOLR1 IHC and HRD Status only performed for epithelial ovarian cancer. ^Ki-67 IHC only for early stage breast cancer. * Not available in all locations. |
Place an order today for a comprehensive, personalized Caris profiling report.
Sufficient tumor content (>20% tumor nuclei) must be present to complete all analyses. If you have any questions, please contact Customer Support at (888) 979-8669.
Technical Information | IHC | CISH |
---|---|---|
Sample Requirements (see requisition for full details) |
1 unstained slide at 4μm thickness from FFPE block, with evaluable tumor present, per IHC test | 1 unstained slide at 4μm thickness from FFPE block, with at least 100 evaluable tumor cells present, per CISH test |
Sensitivity/Specificity | >95% | >95% |
Technical Information | NGS (Whole Exome – DNA) | NGS (Whole Transcriptome – RNA) |
---|---|---|
Sample Requirements | FFPE block or 10 unstained slides with a minimum of 20% malignant origin for DNA and 10% malignant origin for RNA. Needle biopsy is also acceptable (4-6 cores). | |
Tumor Enrichment (when necessary) | Microdissection to isolate and increase the number of cancer cells to improve test performance and increase the chance for successful testing from small tumor samples | |
Number of Genes | 23,000+ genes | 23,000+ genes |
Average Depth
of Coverage (DNA) Average Read Count (RNA) |
800x for clinical genes | 23 million reads |
Positive Percent Agreement (PPA) | >95% for base substitutions at ≥ 5% mutant allele frequency; >95% for indels at ≥ 5% mutant allele frequency; >90% for copy number alterations (amplifications ≥ 6 copies) |
>97% |
Negative Percent Agreement (NPA) | >99% | >99% |
Viruses* | HPV 16 & 18 (Head & Neck, Anal, Genital, CUP) | |
Genomic Signatures/Other | Genomic Loss of
Heterozygosity (gLOH) Homologous Recombination Deficiency (HRD)* Microsatellite Instability (MSI) Tumor Mutational Burden (TMB) Human Leukocyte Antigen (HLA) Genotype* |
|
* Not available in all locations. |
ABL | ABL1 | ACVR1 | AIP | AKT1 | AKT2 | AKT3 | ALK | AMER1 | APC |
AR | ARAF | ARHGAP26 | ARHGAP35 | ARID1A | ARID2 | AR-V7 | ASXL1 | ATM | ATR |
ATRX | AXIN1 | AXIN2 | AXL | B2M | BAP1 | BARD1 | BCL2 | BCL9 | BCOR |
BCR | BLM | BMPR1A | BRAF | BRCA1 | BRCA2 | BRD3 | BRD4 | BRIP1 | BTK |
CALR | CARD11 | CASP8 | CBFB | CCND1 | CCND2 | CCND3 | CD79B | CDC73 | CDH1 |
CDK12 | CDK4 | CDK6 | CDKN1B | CDKN2A | CHEK1 | CHEK2 | CIC | CREBBP | CSF1R |
CTCF | CTNNA1 | CTNNB1 | CXCR4 | CYLD | CYP17A1 | DDR2 | DICER1 | DNMT3A | EGFR |
EGFR vIII | EGLN1 | ELF3 | EP300 | EPHA2 | ERBB2 | ERBB3 | ERBB4 | ERCC2 | ERG |
ESR1 | ETV1 | ETV4 | ETV5 | ETV6 | EWSR1 | EXO1 | EZH2 | FANCA | FANCB |
FANCC | FANCD2 | FANCE | FANCF | FANCG | FANCI | FANCL | FANCM | FAS | FAT1 |
FBXW7 | FGFR1 | FGFR2 | FGFR3 | FGFR4 | FGR | FH | FLCN | FLT1 | FLT3 |
FLT4 | FOXA1 | FOXL2 | FUBP1 | FYN | GALNT12 | GATA3 | GLI2 | GNA11 | GNA13 |
GNAQ | GNAS | H3F3A | H3F3B | HDAC1 | HIST1H3B | HIST1H3C | HNF1A | HOXB13 | HRAS |
IDH1 | IDH2 | INSR | IRF4 | JAK1 | JAK2 | JAK3 | KDM5C | KDM6A | KDR |
KEAP1 | KIF1B | KIT | KLF4 | KMT2A | KMT2C | KMT2D | KRAS | LCK | LYN |
LZTR1 | MAML2 | MAP2K1 | MAP2K2 | MAP2K4 | MAP3K1 | MAPK1 | MAPK3 | MAST1 | MAST2 |
MAX | MED12 | MEF2B | MEN1 | MET | MET Exon 14 Skipping | MGA | MITF | MLH1 | MLH3 |
MPL | MRE11 | MSH2 | MSH3 | MSH6 | MSMB | MST1R | MTOR | MUSK | MUTYH |
MYB | MYC | MYCN | MYD88 | NBN | NF1 | NF2 | NFE2L2 | NFKBIA | NOTCH1 |
NOTCH2 | NPM1 | NRAS | NRG1 | NSD1 | NTHL1 | NTRK1 | NTRK2 | NTRK3 | NUMBL |
NUTM1 | PALB2 | PARP1 | PBRM1 | PDGFRA | PDGFRB | PHOX2B | PIK3CA | PIK3CB | PIK3R1 |
PIK3R2 | PIM1 | PKN1 | PMS1 | PMS2 | POLD1 | POLD2 | POLD3 | POLD4 | POLE |
POLQ | POT1 | PPARG | PPP2R1A | PPP2R2A | PRDM1 | PRKACA | PRKAR1A | PRKCA | PRKCB |
PRKDC | PTCH1 | PTEN | PTPN11 | RABL3 | RAC1 | RAD50 | RAD51B | RAD51C | RAD51D |
RAD54L | RAF1 | RASA1 | RB1 | RELA | RET | RHOA | RNF43 | ROS1 | RPA1 |
RPA2 | RPA3 | RPA4 | RSPO2 | RSPO3 | RUNX1 | SDHA | SDHAF2 | SDHB | SDHC |
SDHD | SETD2 | SF3B1 | SMAD2 | SMAD4 | SMARCA4 | SMARCB1 | SMARCE1 | SMO | SOCS1 |
SPEN | SPOP | SRC | SSBP1 | STAG2 | STAT3 | STK11 | SUFU | SUZ12 | TCF7L2 |
TERT | TET2 | TFE3 | TFEB | THADA | TMEM127 | TMPRSS2 | TNFAIP3 | TNFRSF14 | TP53 |
TRAF7 | TSC1 | TSC2 | U2AF1 | VHL | WRN | WT1 | XPO1 | XRCC1 | XRCC2 |
YES1 |
Sufficient tumor content (>20% tumor nuclei) must be present to complete all analysis. If you have questions, please contact Customer Support at (888) 979-8669.
Tumor content: >20% tumor nuclei
Paraffin Block (Preferred)
Formalin fixed tissue block (including core-needle biopsies, fine-needle aspirates or malignant fluid)
Unstained Slides
25 slides
10% neutral buffered formalin
Four to six (4-6) biopsies with 18 gauge needle preferred
Six to ten (6-10) biopsies with 22 needle accepted
The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted.
Download Profile Menu for US and Intl PDF >
Whole Exome Sequencing (WES)
Whole Transcriptome Sequencing (WTS)
Select tumor type to see specific tests to be performed.
Additional Information:
"*" indicates required fields
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |